Haleon (Haleon) Debt-to-Equity : N/A (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Haleon Debt-to-Equity?

Haleon's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0 Mil. Haleon's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0 Mil. Haleon's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Haleon's Debt-to-Equity or its related term are showing as below:

HLN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.38 Max: 0.64
Current: 0.57

During the past 5 years, the highest Debt-to-Equity Ratio of Haleon was 0.64. The lowest was 0.02. And the median was 0.38.

HLN's Debt-to-Equity is ranked worse than
69.99% of 853 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs HLN: 0.57

Haleon Debt-to-Equity Historical Data

The historical data trend for Haleon's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon Debt-to-Equity Chart

Haleon Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.02

0.04

0.64

0.57

Haleon Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial									N/A	0.60	N/A	0.57	N/A

Competitive Comparison of Haleon's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haleon's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haleon's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Haleon's Debt-to-Equity falls into.

Haleon Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Haleon's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(830.38	+	11139.241)	/	21020.253
	=	0.57

Haleon's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Haleon (NYSE:HLN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Haleon Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Haleon's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Haleon (Haleon) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (NYSE:HLN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

HLNCF:USA HLN1:Mexico HLNl:UK HLN:UK H6D0:Germany

Address

The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY

Website

https://www.haleon.com

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.